MG-D-1509
/ Metagone Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
August 22, 2023
Camrelizumab Plus Rivoceranib vs Sorafenib in Unresectable Hepatocellular Carcinoma. The reported mOS is the highest reported mOS (22.1m) thus far in the context that mOS for Sorafenib is a lot higher than expected (15.2m)...
June 30, 2023
Liver cancer, new results for double immunotherapy
(breakinglatest.news)
- "'The long-term survival data from the Himalaya study are unique in the panorama of advanced hepatocellular carcinoma - says Lorenza Rimassa..."
Media quote
July 06, 2023
Assessing treatment options for hepatocellular carcinoma
(YouTube)
- "Lorenza Rimassa, MD...discusses different therapies for hepatocellular carcinoma (HCC)."
Interview • Video
June 25, 2022
The Synergistic Cytotoxic Effects of GW5074 and Sorafenib by Impacting Mitochondrial Functions in Human Colorectal Cancer Cell Lines.
(PubMed, Front Oncol)
- "In summary, the C-RAF inhibitor GW5074 might potentiate the cytotoxicity of the B-RAF inhibitor sorafenib mediated through mitochondrial dysfunctions, suggesting that GW5074 potentially serves as a sensitizer for sorafenib application to reduce the risk of drug resistance of CRC treatment. Our findings also provide novel insights on using C-RAF inhibitors combined with sorafenib, the current CRC therapeutic drug choice, in CRC treatment."
Journal • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Metabolic Disorders • Oncology • Solid Tumor • BRAF
April 24, 2022
Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors.
(PubMed, J Clin Med)
- "Co-administration therapy of GW5074 and sorafenib demonstrated a favorable safety profile and showed anti-tumor activity in a variety of tumor types. However, the solubility of GW5074 is not satisfactory. A future phase 2a trial will be carried out using the new salted form that has been proven to be more effective."
Journal • P1 data • Hypertension • Oncology • Solid Tumor • CTCs
April 26, 2021
Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
(clinicaltrials.gov)
- P1; N=17; Completed; Sponsor: Metagone Biotech Inc.; Phase classification: P1/2 ➔ P1
Clinical • Phase classification • Oncology • Solid Tumor
September 02, 2020
Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
(clinicaltrials.gov)
- P1/2; N=17; Completed; Sponsor: Metagone Biotech Inc.; Recruiting ➔ Completed; N=33 ➔ 17; Trial completion date: Dec 2019 ➔ Jul 2020
Clinical • Enrollment change • Trial completion • Trial completion date • Oncology • Solid Tumor
1 to 7
Of
7
Go to page
1